Clinical trial · Interventional
Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients
NCT01601314CI-TRIAL-00031220MAGNAcompletedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the relationship between magnesium sulphate administration and levels of S100B protein in serum of patients undergoing supratentorial brain parenchymal resection.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Tumor | Brain Neoplasm | ALIAS | 0.90 |
| Seizures (Incl Subtypes) | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnesium Sulfate | Drug | — | UNRESOLVED |
| Sodium Chloride | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- magnesium sulphate
- description
- The patients who are going to receive Magnesium Sulphate
- interventionNames
- Drug: Magnesium Sulfate
- type
- PLACEBO_COMPARATOR
- label
- Control
- description
- Patients who are going to receive Sodium Chloride 0.9%
- interventionNames
- Other: Sodium Chloride
Primary outcomes (1)
- measure
- Serum S100B protein
- timeFrame
- 2 hours after the end of the surgery
Secondary outcomes (7)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Male and females older than 18 years. * Undergoing supratentorial parenchyma resection surgery. * Capable of collaborate on probes and explorations included in the study. * Signature the written informed consent form. Exclusion Criteria: * Life expectancy less than 12 months due to the suspected histological type of tumour. * Hypothalamic-pituitary axis illness. * Presence of Melanoma previously. * Glomerular filtration rate less than 60 mL/min. * Thyroid or parathyroid glands pathology. * Myasthenia gravis. * Respiratory depression. * Pregnancy or breastfeeding.
References
Publications (0)
Data not yet available
No reference posted for this study.